New York can­cer cen­ter launch­es 'his­toric' JV to bring Cuban-de­vel­oped can­cer drugs to US

Some of the next wave of im­munother­a­pies de­signed to bol­ster check­point in­hibitors will orig­i­nate from Cu­ba — if Roswell Park Com­pre­hen­sive Can­cer Cen­ter’s lat­est ven­ture flour­ish­es ac­cord­ing to plan.

The can­cer re­search and treat­ment cen­ter, lo­cat­ed in Buf­fa­lo, NY, is launch­ing a joint ven­ture biotech with Ha­vana-based Cen­ter for Mol­e­c­u­lar Im­munol­o­gy (CIM), which de­vel­oped a can­cer vac­cine that Roswell Park has been study­ing. Dubbed In­no­v­a­tive Im­munother­a­py Al­liance, the com­pa­ny will con­duct fur­ther stud­ies in Cu­ba on CIMAvax as well as three oth­er ex­per­i­men­tal can­cer drugs from CIM, with the ul­ti­mate goal of gain­ing FDA ap­proval in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER